Results 291 to 300 of about 180,947 (337)

Enteral Nutrition in Pediatric Crohn's Disease: New Perspectives. [PDF]

Nutrients
Brindicci VF, Grieco R, Ruiz RG, Cardile S, Capriati T, Trovato CM, Bolasco G, Knafelz D, Bracci F, Alterio A, Ferretti F, Elia D, Spinetti E, Francavilla R, Diamanti A.   +14 more
europepmc   +1 more source

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
Eating disorders are common among individuals with IBD, with prevalence estimates ranging from 3% to 14% depending on the assessment method. Findings highlight the need for validated screening tools tailored to IBD. ABSTRACT Background and Aims Disentangling whether disordered eating is a cause, consequence or manifestation of inflammatory bowel ...
Quinn Goddard, Ante Markovinović, Paul E. Ronksley, Cynthia H. Seow, Christopher Ma, Abdel‐Aziz Shaheen, Gilaad G. Kaplan   +6 more
wiley   +1 more source

Correction: Therapeutic mechanisms of exclusive enteral nutrition in crohn's disease. [PDF]

Semin Immunopathol
Krammel T, Nie J, Häcker D, Schwerd T, Aguanno D, Haller D.   +5 more
europepmc   +1 more source

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

British Journal of Pharmacology, EarlyView.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

Efficacy of mesenchymal stem cell-based therapies in the treatment of perianal fistulizing Crohn’s disease: a systematic review and meta-analysis [PDF]

Lucas Guillo, Robinson Gravier Dumonceau, Mélanie Velier, Mélanie Serrero, Fanny Grimaud, Florence Sabatier, Jérémy Magalon   +6 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Effects of Modified Crohn's Disease Exclusion Diet as Adjunctive Therapy on Clinical Remission and Nutrition in Pediatric Crohn's Disease: A Real-World Study from China. [PDF]

Children (Basel)
Li D, Kong Y, Ye X, Zhang T, Yu F, Wu J.
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Postoperative Recurrence in Crohn's Disease: Pathophysiology, Risk Stratification, and Management Strategies. [PDF]

J Clin Med
Bertin L, Semprucci G, Cavagna C, Zanconato M, Scarpa M, Ruffolo C, Angriman I, Buda A, Riguccio G, Zingone F, Barberio B, Savarino EV.   +11 more
europepmc   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source